The first biosimilar to rituximab for patients with non-Hodgkin lymphoma has received FDA approval. Rituximab-abbs is indicated for adults with CD20-positive, B-cell non-Hodgkin lymphoma. It can be used as a single agent or in combination with chemotherapy.
Biosimilars are biological products that are approved based on data showing that they’re highly similar to a biological product that already has received FDA approval. Biosimilars can have no clinically meaningful differences in safety and effectiveness, and they must meet other criteria specified by law.
Voelker R. A First in Non-Hodgkin Lymphoma Treatment. JAMA. 2019;321(1):23. doi:10.1001/jama.2018.20501
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: